Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Corporate Presentation

SEC Filings

Form Description Filing date View
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13D

Filing by person(s) reporting owned shares of common stock in a public company >5%

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

Data provided by Kaleidoscope.

Events and Presentations